Research and Development

Selvita is developing novel small molecule therapies that address emerging targets in oncology with industry-leading research expertise supported by a research services division.

Pipeline candidates apply diverse mechanisms directed at kinases, synthetic lethality pathways, immuno-oncology pathways and other cancer-related targets.

SEL24/MEN1703 is a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group in clinical development for the treatment of acute myeloid leukemia.

SEL120 is a CDK8 kinase inhibitor with potential for development in indications including hematological malignancies and solid tumors.